Skip to content

Inspection prep notes · Data and records

Audit trails and computerized systems

Also called: audit trail, computerized system

FDA looks less at whether an audit trail function exists than at whether its records are actually reviewed and the system's privileges, validation and backups are controlled. The findings below are quoted from warning letters and FDA 483s.

What inspectors cited

1Audit trails were not reviewed

During the review of analytical system audit trails for final release testing of finished OTC drug products, our inspection found that your firm does not review audit trails and raw analytical data captured by these analytical instruments.

FDA Warning Letter · Wisconsin Pharmacal Company, LLC · 2025-09-02 · View document

Quality Assurance does not periodically review audit trails or test results stored in the [redacted] instrument.

FDA 483 · PQ Pharmacy LLC · 2026-09-22 · View document

2Analysts' administrative privileges were not restricted

For example, your analysts had administrative rights on your chromatographic systems that allowed them to alter and delete data, files, and folders, including your spreadsheet used for assay calculations.

FDA Warning Letter · Unipack LLC · 2025-12-30

[redacted] employees authorized to perform HPLC analyses have administrative user roles in the [redacted] chromatography data system.

FDA 483 · Staska Pharmaceuticals, Inc · 2026-05-08 · View document

3Software was not validated

Your GC laboratory instrument was not adequately qualified because you failed to validate the control software or enable audit trails, and the GC data file creation and modification dates were not accurate.

FDA Warning Letter · Laboratorios Jaloma S.A. de C.V. · 2026-06-02 · View document

You lack documented validation showing that the application software that generates and stores details of [redacted] cleaning/decontamination meet Part 11 requirements for electronic records.

FDA 483 · Apollo Care LLC · 2025-07-31 · View document

4Electronic data were not backed up

Furthermore, your firm did not adequately maintain backups of data generated by your laboratory equipment.

FDA Warning Letter · NWL Netherlands Services B.V. · 2025-05-20 · View document

Procedure S403400, Section 7.9.23 indicate [redacted] data can be backed up to external storage. However, your CEO confirmed that no backup is performed to prevent data loss.

FDA 483 · PQ Pharmacy LLC · 2026-09-22 · View document

5User accounts were shared instead of individual

Specifically, Excel worksheets used to perform chromatogram calculations were not retained, and access accounts to the GC and HPLC workstations were shared by job title and were not attributable to the individual analyst.

FDA Warning Letter · Taizhou Kangping Medical Science and Technology Co., Ltd. · 2025-11-11

GC which uses Chrome 2004 crt software (equipment # QC/INST/08) has a common user name and password shared by four (4) employees.

FDA 483 · Zen Chemicals Pvt. Ltd · 2026-10-19 · View document

Questions to check against your procedures

  1. Are audit trails and raw analytical data from instruments used for final release testing reviewed?
  2. Are the staff who perform analyses without administrative rights that let them alter or delete data, files and folders?
  3. Are user names and passwords on instrument workstations individual and not shared among staff, so that access accounts are attributable to the individual analyst?
  4. Is the control software of laboratory instruments validated, and are audit trails enabled?
  5. Is there documented validation showing that application software that generates and stores electronic records meets Part 11 requirements?
  6. Is data generated by laboratory equipment backed up as the procedure states?

Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-15.

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.